Associate Professor Thomas Naderer


  • Host-Pathogen Interactions
  • Molecular microbiology
  • Alternative approaches to control infections
  • Repurposing drugs that inhibit host factors

Associate Professor Thomas Naderer and his team specialise in imaging the dynamic host-pathogen interactions using live-cell, super resolution and electron microscopes. They use biochemical and molecular approaches to identify how microbial pathogens hijack host pathways during infections. By employing CRISPR whole genome screens in macrophages, they identify how the immune system controls infections with the aim to develop host-targeted approaches in infectious diseases. The Naderer lab also use animal models of infections and human stem cell-based approaches to study lung and sexually transmitted infections.

Associate Professor Thomas Naderer leads the host-pathogen interaction laboratory at Monash Biomedicine Discovery Institute since 2012. After completing his undergraduate studies at the University of Vienna, Austria, and a Masters at the University of Nottingham, UK,  Associate Professor Thomas Naderer obtained his PhD from the University of Melbourne, Australia in 2004. His work is supported from national funds, including an ARC Future Fellowship, NHMRC Project and Ideas Grants. He worked previously at the Bio21, University of Melbourne, before joining the NHMRC Program on Cellular Microbiology headed by Professor Trevor Lithgow, Monash University.


  • Imaging dynamic host-pathogen interactions.
  • Bacterial membrane vesicles as delivery and vaccine candidates.
  • AMR due to outer membrane vesicle formation.
  • Metabolic interactions between host cells and pathogens.
  • Microbial toxins and their activity in host cells.
  • Immune responses to microbial infections.


  • Host-directed antimicrobials.
  • Understanding fundamental host-pathogen interactions.
  • Alternative approaches to control infections by developing host-directed therapies.
  • Repurposing of drugs that inhibit host factors and prevent infections.


  • Head: Centre to Impact AMR R&D Facility - Pre-clinical Testing